5-[5-(4-Hydroxyphenyl)pyrimidin-2-yl]benzene-1,3-diol | 1402432-98-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-[5-(4-Hydroxyphenyl)pyrimidin-2-yl]benzene-1,3-diol
• 英文别名: 5-[5-(4-hydroxyphenyl)pyrimidin-2-yl]benzene-1,3-diol
• CAS: 1402432-98-7
• 化学式: C₁₆H₁₂N₂O₃
• 分子量: 280.283
• InChiKey: JJOZZQINANNZDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.5
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(3,5-Dimethoxyphenyl)-5-(4-methoxyphenyl)pyrimidine 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 生成 5-[5-(4-Hydroxyphenyl)pyrimidin-2-yl]benzene-1,3-diol
  参考文献：
  名称：

  Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine

  摘要：

  Ribonucleotide reductase inhibitors enhance the anti-HIV-1 activities of a variety of nucleoside analogs, including those that act as chain terminators and those that increase the HIV-1 mutation rate. However the use of these ribonucleotide reductase inhibitors is limited by their associated toxicities. The hydroxylated phytostilbene resveratrol has activity in a host of systems including inhibition of ribonucleotide reductase and has minimal toxicity. Here we synthesized derivatives of resveratrol and examined them for anti-HIV-1 activity and their ability to enhance the antiviral activity of decitabine, a nucleoside analog that decreases viral replication by increasing the HIV-1 mutation rate. The data demonstrates that six of the derivatives have anti-HIV-1 activity greater than resveratrol. However, only resveratrol acted in synergy with decitabine to inhibit HIV-1 infectivity. These results reveal novel resveratrol derivatives with anti-HIV-1 activity that may have mechanisms of action that differ from the drugs currently used to treat HIV-1. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.108

文献信息

• Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine
  作者：Christine L. Clouser、Jay Chauhan、Matthew A. Bess、Jessica L. van Oploo、Ding Zhou、Sarah Dimick-Gray、Louis M. Mansky、Steven E. Patterson

  DOI：10.1016/j.bmcl.2012.08.108

  日期：2012.11

  Ribonucleotide reductase inhibitors enhance the anti-HIV-1 activities of a variety of nucleoside analogs, including those that act as chain terminators and those that increase the HIV-1 mutation rate. However the use of these ribonucleotide reductase inhibitors is limited by their associated toxicities. The hydroxylated phytostilbene resveratrol has activity in a host of systems including inhibition of ribonucleotide reductase and has minimal toxicity. Here we synthesized derivatives of resveratrol and examined them for anti-HIV-1 activity and their ability to enhance the antiviral activity of decitabine, a nucleoside analog that decreases viral replication by increasing the HIV-1 mutation rate. The data demonstrates that six of the derivatives have anti-HIV-1 activity greater than resveratrol. However, only resveratrol acted in synergy with decitabine to inhibit HIV-1 infectivity. These results reveal novel resveratrol derivatives with anti-HIV-1 activity that may have mechanisms of action that differ from the drugs currently used to treat HIV-1. (C) 2012 Elsevier Ltd. All rights reserved.